L’empagliflozine (Jardiance®), un nouvel inhibiteur SGLT-2 dans le traitement du diabète de type 2 Pourquoi ? Comment ? Avec quels résultats ?
(2015) Louvain médical — Vol. 134, n° 7, p. 339-346 (2015)
Files
2015_Buysschaert_LM_1347_339-346.pdf
Restricted Access - Adobe PDF
- 219.04 KB
Details
- Authors
- Abstract
- (en) [Empagli ozine (Jardiance®), a novel sglt-2 inhibitor, for the treatment of type 2 diabetes Why? How? And what are the results?] SGLT-2 inhibitors, when administered to patients with Type 2 diabetes, are associated with an improvement in glycemic control, due to their glucoretic effect, which is associated with weight loss and reduction in blood pressure levels.Empagliflozine (Jardiance®) is a new SGLT-2 inhibitor that has been available in Belgium since July 2015. this paper sought to review recent scientific data pertaining to controlled trials involving the administration of empagliflozin versus placebo or active comparators (sitagliptin; glimepiride) in Type 2 diabetic patients. Jardiance® was associated with a reduction in HbA1c, along with weight loss and decreased blood pressure levels. Side-effects included mild urinary and genital infections. In Belgium, Jardiance® has been authorized for use in bi - or tritherapy comprising basal insulin
- Affiliations
Citations
Buysschaert, M. (2015). L’empagliflozine (Jardiance®), un nouvel inhibiteur SGLT-2 dans le traitement du diabète de type 2 Pourquoi ? Comment ? Avec quels résultats ? Louvain médical, 134(7), 339-346. https://hdl.handle.net/2078.5/66850 (Original work published 2015)